• Promaxo announced the initial close of Series C financing on October 22, 2026, with participation from New Science Ventures and Amara Ventures.
• The prostate MRI platform developer also closed a $100 million credit facility.
• Its portable MRI system has FDA 510(k) clearance for prostate biopsy and treatment across a broad range of healthcare settings.
• The new capital will support manufacturing expansion, backlog reduction and new regulatory filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. New Science Ventures LLC published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.